| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
|
|
08-29-2017, 04:25 PM
|
#1 | ||
|
|||
|
Junior Member
|
This was disappointing to see:
Acorda Therapeutics Inc - Acorda Receives Refusal to File Letter from FDA for INBRIJA™ (CVT-3 1, levodopa inhalation powder) New Drug Application Fortunately, it seems that Acorda should be able to provide the additional information, but it is unfortunate that there will be a delay. Oral Sinemet is going badly for my mom these days and we were very keen to try another delivery route (not much luck with agonists either, and she is currently trying Xadago). Did anyone on the forum participate in the trial, and if so, would you be willing to share your experiences? Thanks.
__________________
Looking for different options for my mom, born 1946 and dX with PD in 2010. |
||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Add a Letter, Drop a Letter Game | Games | |||
| UCB Receives Complete Response Letter from U.S. FDA Regarding Neupro® (Rotigotine) | Parkinson's Disease | |||
| Ampyra - Anyone having trouble with Acorda? | Multiple Sclerosis | |||
| FDA delays ruling on Acorda's MS drug until Jan | Multiple Sclerosis | |||
Acorda receives refusal to file letter from FDA for Inbrija
Hybrid Mode
